Rallybio Corporation (RLYB) - News Archive

Rallybio Delivers Q3 2025 Financial Results and Business Developments NEW HAVEN, Conn. Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company dedicated to translating scientific advances into transf...

Rallybio Receives $12.5 Million Milestone Payment from Recursion for REV102 Advancements Rallybio Corporation, a clinical-stage biotechnology company listed on Nasdaq as RLYB, recently announced a significant developmen...

Rallybio Sells Interest in Rare Disease Program to Recursion Pharmaceuticals for Up to $25 Million NEW HAVEN, Conn. Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company focused on the development...

Rallybio Corporation, a rapidly progressing clinical-stage biotechnology company committed to developing transformative therapies for patients facing rare diseases, has achieved noteworthy milestones in drug discovery a...

Rallybio Corporation, a clinical-stage biotechnology company, has embarked on a transformative journey to address the challenges posed by fetal and neonatal alloimmune thrombocytopenia (FNAIT). This article provides ins...

: Recent findings presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting shed light on the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) as a potential tre...

Understanding FNAIT Risks Across Diverse Populations: Insights from Rallybio s Research Rallybio Corporation, a clinical-stage biotech firm based in New Haven, Connecticut, is set to unveil critical findings related to...

In the hallowed chambers of medical advancement, the Rallybio Corporation, a beacon within the ever-evolving landscape of biotechnology, unveiled a significant milestone befitting the relentless pursuit of alleviating h...

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse PopulationsNew Haven, Conn. (Date) - Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechno...

In an exciting development, Rallybio Corporation, a clinical-stage biotechnology company focused on developing groundbreaking therapies for patients afflicted with rare diseases, has shared its financial results for the...